PP-001

DRUG2 trials

Sponsors

Panoptes Pharma GmbH

Conditions

KeratoconjunctivitisNon-infectious UveitisOcular Surface Disease

Phase 1

A Safety Study of Intravitreal PP-001 in Patients With Chronic, Non-Infectious Uveitis

CompletedNCT03634475

Panoptes Pharma GmbHNon-infectious Uveitis

Start: 2017-01-31End: 2019-04-30Updated: 2024-10-09

A Phase I Study of PP-001 Eye Drops in Healthy Adult Volunteers

CompletedNCT03769454

Panoptes Pharma GmbHKeratoconjunctivitis, Ocular Surface Disease

Start: 2018-11-20End: 2022-03-15Updated: 2024-01-12

Related Papers

A new small molecule DHODH-inhibitor [KIO-100 (PP-001)] targeting activated T cells for intraocular treatment of uveitis — A phase I clinical trial

Frontiers in Medicine2022-10-173 citations